On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayMar 07, 2017 3:42 pm

NetworkNewsBreaks – Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) ‘Buy’ Rating, $25 PT Reiterated at Aegis Capital

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) following the company’s recent report of financial results for the year ended December 31, 2016. Revenue was $174,000 for the year ended December 31, 2016, compared to $66.7 million for the year ended December 31, 2015. However, because Concert is a clinical-stage company, Aegis cited the events surrounding clinical trials rather than financials. In its earnings release, Concert also announced an asset acquisition agreement in which Vertex Pharmaceuticals will acquire Concert’s CTP-656 for up to $250 million. Concert expects…

Continue Reading

TuesdayMar 07, 2017 3:40 pm

NetworkNewsBreaks – Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) ‘Buy’ Rating, $21 PT Reiterated at Aegis Capital

Aegis Capital reiterated its ‘Buy’ rating and $21 price target on shares of Akebia Therapeutics (NASDAQ: AKBA). The biopharmaceutical company recently announced financial results for the fourth quarter and full year ended December 31, 2016, though Aegis focused on the company’s clinical trials and collaboration agreements for the reiteration. As reported in Akebia’s earnings release, full-year 2016 highlights include: the initiation of the global phase 3 INNO2VATE program to evaluate vadadustat in dialysis-dependent patients with anemia associated with chronic kidney disease (CKD); entered into a collaboration with Otsuka Pharmaceutical Co., Ltd in which the companies equally share the costs of…

Continue Reading

TuesdayMar 07, 2017 12:22 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Teams with GlobalSim to Launch VR Construction Crane Simulator

Education technology company ProBility Media Corp. (OTCQB: PBYA) this morning announced that it has teamed up with GlobalSim, Inc., a leading provider of simulators and training systems for a variety of industries, to introduce a virtual reality training simulator targeting the crane industry. The two companies have executed an exclusive agreement through which GlobalSim will provide the portable VR Construction Crane hardware and the eLearning software, while ProBility will commercialize the product through its extensive sales channels in both the United States and Canada. “Providing high quality training to the $35 billion crane industry is paramount in our strategy of…

Continue Reading

TuesdayMar 07, 2017 11:25 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 7, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MYSZ 34.45% – News: Plans to open a subsidiary in Poland NAKD 17.93% – News: Presenting at the 29th Annual ROTH Conference on March 14 BNKL 17.26% – News: Appoints marketing director GRLD 12.50% – News: Chairman accepts shares of common stock in lieu of salary HPJ 10.20% – News: Posts unaudited Q4, FY 2016 financial results MOSY 6.63% – News: Regains NASDAQ compliance STLT 5.50% – News: Presenting at 29th Annual ROTH Conference…

Continue Reading

TuesdayMar 07, 2017 11:25 am

NetworkNewsBreaks – Aeterna Zentaris, Inc. (NASDAQ: AEZS) Receives EMA Pediatric Committee Agreement on PIP for Macrilen™

Shares of Aeterna Zentaris (NASDAQ: AEZS) are 6% higher in morning trade after the company said the European Medicines Agency’s (EMA) Pediatric Committee (PDCO) has agreed to the company’s Pediatric Investigation Plan (PIP) for Macrilen™. PDCO also agreed that Aeterna may defer conducting the PIP until after it files a Marketing Authorization Application (MAA) for the use of Macrilen™ for the evaluation of adult growth hormone deficiency. “PDCO’s agreement that we may defer conducting our PIP, allowing us to go forward with an MAA in adults prior to initiating of the pediatric development program, is an important step forward in…

Continue Reading

TuesdayMar 07, 2017 11:22 am

NetworkNewsBreaks – TerraForm Global (NASDAQ: GLBL) Inks Definitive Merger Agreement with Brookfield (NYSE: BAM)

Shares of TerraForm Global, Inc. (NASDAQ: GLBL) are 16% higher after the company announced its definitive merger agreement with Brookfield Asset Management Inc. (NYSE: BAM). Per the agreement, Brookfield will acquire TerraForm Global for approximately $787 million in cash and will assume approximately $455 million in net debt, representing an enterprise value of approximately $1.3 billion. TerraForm Global owns and operates, or has contracts to acquire, a fleet of 31 wind and solar power plants totaling 952 MW of capacity spread across Brazil, India, China, South Africa, Thailand, Malaysia and Uruguay. The transaction is expected to be completed in the…

Continue Reading

TuesdayMar 07, 2017 10:14 am

NetworkNewsBreaks – Net Element’s (NASDAQ: NETE) PayOnline Providing Single-Click Payment Services for RUNET-ID

Global payment technology provider Net Element, Inc. (NASDAQ: NETE) this morning announced that RUNET-ID, Russia’s largest Internet resource dedicated to the domestic IT industry and telecommunication events, has chosen PayOnline for its secure, single-click payment acceptance services. PayOnline will simplify the payment process for RUNET-ID’s user base of more than 500,000 IT professionals, enabling access to single-click transactions following a one-time entry of payment details. Per this morning’s update, this convenient transaction capability simplifies the payment process without compromising security. “We are honored to be recognized as the best payment partner for Russia's largest Internet resource with access to over…

Continue Reading

TuesdayMar 07, 2017 9:39 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) CEO Featured in Audio Interview with NetworkNewsWire

Multifaceted financial news and publishing company NetworkNewsWire this morning announced the online availability of a new audio interview with ORHub, Inc. (OTC: ORHB) CEO Colt Melby. In the interview, Melby discusses ORHub’s operations, particularly as they relate to the company’s cloud-based health care software-as-a-service platform, which aims to decrease medical costs while improving outcomes in surgical care. Melby notes that ORHub’s innovative software platform “empowers care providers at every level of the surgical process to collaborate, organize, deliver, measure and reimburse in one intuitive, easy-to-use program.” The software is currently implemented in two major hospitals in California. Before wrapping up…

Continue Reading

MondayMar 06, 2017 1:56 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 6, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ETST 40.72% – News: Posts update, timeline on cannabinoid-based nutraceutical patent and generic pharmaceutical DXTR 42.11% – News: Presents positive data at Scandinavian Society for Research in Cardiothoracic Surgery MCIG 26.44% – News: Posts Q3 financial results NEPH 6.25% – News: Receives FDA 510(k) to market EndoPur™ Endotoxin 10" Filter CCIH 16.50% – News: Enters definitive agreements to sell data center assets QRHC 10.46% – News: Presenting at 29th Roth Annual Growth Stock Conference…

Continue Reading

MondayMar 06, 2017 1:52 pm

NetworkNewsBreaks – CytoSorbents Corp. (NASDAQ: CTSO) Receives Aegis Capital ‘Buy’ Rating, Reports Record Product Sales Growth

CytoSorbents (NASDAQ: CTSO) has received a ‘Buy’ rating and $20 price target from Aegis Capital Corp. following the company’s recent report of operational and financial results for the fiscal year ended December 31, 2016. The company reported a total revenue including both product sales and grant income in 2016 of approximately $9.5 million, almost doubling from $4.8 million in 2015. CytoSorb® also reports that product sales increased 103% to $8.2 million for fiscal 2016 compared to $4.0 million in fiscal 2015. Additionally, the company’s product sales were $2.6 million in the fourth quarter of 2016, the sixth consecutive quarter of…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217